Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Receivables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Receivables for 4 consecutive years, with $568257.0 as the latest value for Q4 2025.

  • Quarterly Receivables fell 51.31% to $568257.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $568257.0 through Dec 2025, down 51.31% year-over-year, with the annual reading at $568257.0 for FY2025, 51.31% down from the prior year.
  • Receivables for Q4 2025 was $568257.0 at bioAffinity Technologies, up from $476133.0 in the prior quarter.
  • The five-year high for Receivables was $1.7 million in Q2 2024, with the low at $9930.0 in Q3 2022.
  • Average Receivables over 4 years is $713687.1, with a median of $704742.0 recorded in 2023.
  • The sharpest move saw Receivables surged 11109.91% in 2023, then tumbled 74.26% in 2025.
  • Over 4 years, Receivables stood at $20978.0 in 2022, then surged by 3910.04% to $841227.0 in 2023, then soared by 38.74% to $1.2 million in 2024, then tumbled by 51.31% to $568257.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $568257.0, $476133.0, and $441385.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.